ENCEFA has identified an unprecedented mechanism of action by modulating CD38, an age-related target highly expressed in the brain and the immune system, whose expression is highly dysregulated in neuro-degenerative and auto-immune diseases and others pathologies with inflammatory compound.

Thus, Encefa's antibody will adress while a cohesive group of diseases with the same mechanism of action as its range of CD38-drugs.